The Global Viral Clearance Market is expected to reach USD 724.5 million by 2023 from USD 271.2 million in 2018, at a CAGR of 21.7% during the forecast period (2018–2023).
The Research report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the Viral Clearance Market, along with revenue estimate market share analysis.
The key factors driving the growth of this market include growth in the pharmaceutical and biotechnology industries, increasing number of new drug launches, R&D investments in life science, advancements in nanofiltration technology, and the high incidence and large economic burden of chronic diseases.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=62681197
Viral Clearance Market segmentation:
· based on application
· based on end users
· based on regions.
The Major Players Operating in the Viral Clearance Market:
The key players in the global market are Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France), Kedrion (Italy), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany), and ViruSure GmbH (Austria).
Wuxi Biologics (Cayman) (China) dominated the global viral clearance market in 2017. The company’s revenue increased from USD 148.9 million in 2016 to USD 239.6 in 2017; this has helped the company reinforce its position in the market. The company offers its services to over 200 companies globally, which include 13 of the top 20 global pharmaceutical companies. Wuxi maintains 12 viral clearance suites to cater to the growing customer needs worldwide.
Geographical Detailed Analysis for Viral Clearance Market:
The North American region is expected to account for the largest share of the market in 2018
In Canada, increasing pharmaceutical production is expected to boost the growth of the viral clearance market.
However, Asia Pacific is expected to witness the highest growth during the forecast period, owing to increase in generics development and manufacturing, surge in funding for medical research and the presence of a large number of CROs to provide preclinical and clinical research services in China, government initiatives to boost the use of generic drugs, increasing aging population in Japan, rise in pharmaceutical R&D expenditures in India, and the growing pharmaceutical manufacturing in Singapore and Malaysia.
Read More in Detailed (Viral Clearance):
https://www.marketsandmarkets.com/PressReleases/viral-clearance.asp